Edwards Lifesciences (EW) said Thursday that the US Food and Drug Administration approved its Sapien 3 transcatheter aortic valve replacement therapy, or TAVR, for asymptomatic patients with severe aortic stenosis.
The FDA approved the Sapien 3 platform, including Sapien 3, Sapien 3 Ultra, and Sapien 3 Ultra Resilia models, based on compelling results from the Early TAVR trial. The trial demonstrated better outcomes for asymptomatic severe aortic stenosis patients treated with Edwards' TAVR compared to those monitored under standard guidelines, the company said.
Price: 75.37, Change: -0.12, Percent Change: -0.16
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.